BioStem Technologies, Inc. Completes 2016, 2017 Audit of Financial Statements

August 17, 2018


Pompano Beach, FL., Aug. 17, 2018 (GLOBE NEWSWIRE) – BioStem Technologies, Inc. (OTC PINK: BSEM), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine that exponentially improve, extend, and transform the quality of life for patients, announced that an independent auditor has completed the audit of its Annual Financial Statements for the fiscal years ending December 31, 2016 and December 31, 2017. The Company's auditor, D. Brooks and Associates CPA’s, P.A., has now completed two consecutive years of the audits of the Company's financial statements within the guidelines of Generally Accepted Accounting Principles, (GAAP). D. Brooks and Associates CPA’s, P. A. ( is a PCAOB registered accounting firm.


The Company's audited financials can be viewed on the OTC Markets website at or on BioStem Technologies’ corporate website at


With the completion of two years of audited financial statements, the Company has now passed a major milestone to be eligible to file for a public offering.


BioStem Technologies’ CFO Jason Matuszewski stated, " As we move through the process of getting the Company ready for what will be an exciting period of growth, the completion of two years of audits has been a key goal for us. We are very pleased to have completed this critical second piece of our initial audit and we are hopeful that we can now complete the regulatory review process of our offering statement in 2018.”


About BioStem Technologies, Inc. (OTC PINK: BSEM): 

BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.


Forward-Looking Statements: 

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.


BioStem Technologies, Inc.

Phone: 954-380-8342



Twitter: @Biostemtech

Facebook: BioStem Technologies

Investor Relations: Andrew Van Vurst

(954) 380-8342

Share on Facebook
Share on Twitter
Please reload

Featured Posts

BioStem Technologies Releases Third Quarter 2018 Shareholder Update

December 10, 2018

Please reload

Recent Posts
Please reload